Amylin and the Next Wave: CagriSema, Explained

The first generation of GLP-1 medications worked by leaning on one hormonal pathway. The obvious next move, and the one the field is now pursuing, is to combine pathways. CagriSema is a prominent example: it pairs cagrilintide, a long-acting amylin analog, with semaglutide, the familiar GLP-1 agonist. Understanding why that combination is interesting starts with a hormone most people have never heard of.

What amylin does

Amylin is a hormone co-secreted with insulin from the pancreas. It contributes to satiety and slows gastric emptying, and it acts on appetite-regulating regions of the brain through pathways that overlap with, but are distinct from, GLP-1. The reasoning behind combining the two is straightforward: if you engage two complementary appetite and metabolic systems at once, you might get more effect, or a better-tolerated effect, than maxing out either alone.

The mechanistic case for combining amylin and GLP-1 signaling is genuinely sound. Whether that translates into clearly superior real-world results, at acceptable tolerability, is what the trials are still sorting out.

What the data actually show

The pivotal evidence is REDEFINE 1, a 68-week, double-blind, placebo-controlled trial of 3,417 adults with overweight or obesity but without type 2 diabetes, published in The New England Journal of Medicine on June 22, 2025. The results are large by any standard.

Outcome (CagriSema 2.4 mg / 2.4 mg)	Result
Mean weight change, assuming full adherence	−22.7% vs −2.3% placebo
Mean weight change, on a treatment-policy basis	−20.4% vs −3.0% placebo
Participants reaching ≥25% weight loss (adherent)	40.4%
Participants reaching ≥30% weight loss (adherent)	23.1%

That ~20% real-world average puts CagriSema among the most effective obesity pharmacotherapies studied to date.

Points worth holding onto

• The weight loss is large and verified — roughly a fifth of body weight on a treatment-policy basis, well above placebo.
• The comparison to expectations matters. When earlier topline readouts landed below the most optimistic projections, the stock moved sharply — a reminder that pre-trial hype sets traps even when the absolute numbers are strong.
• Tolerability is the swing factor. Gastrointestinal side effects remain the main limiter for this drug class, and how a combination balances efficacy against tolerability is central to its eventual place in care.

Why the combination strategy matters beyond one drug

CagriSema is best understood as one entry in a broader shift. The field is moving from single-pathway agonists toward multi-hormone combinations and co-agonists, on the bet that engaging several metabolic systems yields better outcomes. Amylin is one promising partner; others are in development. The general direction looks real. The specifics, including which combinations win on the efficacy-tolerability tradeoff, are still being worked out trial by trial.

The takeaway

Amylin-plus-GLP-1 is a logical next step, and REDEFINE 1 gives CagriSema a credible, peer-reviewed result: about 20% weight loss over 68 weeks. The honest bottom line is to hold two things at once: the combination approach is genuinely effective and likely here to stay, while the specific question of how much better any single combination is, and at what tolerability cost, is still being answered head-to-head.

Sources

• CagriSema 2.4 mg / 2.4 mg demonstrated 22.7% mean weight reduction in REDEFINE 1, published in NEJM (Novo Nordisk)
• REDEFINE 1: Cagrilintide–Semaglutide Combination Delivers Over 20% Weight Loss (Applied Clinical Trials)